Pharma channel feed

Dems res­ur­rect a scaled back plan for Medicare drug price ne­go­ti­a­tions

4 years ago
R&D

Cal­i­for­nia judge sides with drug­mak­ers in $50B opi­oid law­suit

4 years ago

Ab­b­Vie, Janssen, No­var­tis, Pfiz­er and UCB to joint­ly ad­vance 'dig­i­tal' end­point for atopic der­mati­tis

4 years ago

Mi­graine mar­ket­ing wars? Ab­b­Vie, Bio­haven, Eli Lil­ly, Am­gen lead push for at­ten­tion in new­ly com­pet­i­tive space

4 years ago
Marketing

Eli Lil­ly serves up a win over Biden's HHS in drug dis­count court case

4 years ago

No­vo Nordisk bets big on obe­si­ty: Can mar­ket­ing help it suc­ceed in the no­to­ri­ous­ly tough ther­a­py area?

4 years ago
Marketing

Is that drug ad for me? Peo­ple pay more at­ten­tion to phar­ma DTC for fa­mil­iar con­di­tions, study finds

4 years ago
Marketing

Look­ing to win back in­vestor con­fi­dence, Bio­Marin preps for its ‘largest launch’

4 years ago
Marketing

White House kills off ma­jor drug pric­ing re­forms as De­moc­rats fail to co­a­lesce around Medicare ne­go­ti­a­tion plan

4 years ago

No­var­tis in hot wa­ter again over al­leged kick­backs, re­veal­ing new DoJ probe re­lat­ed to En­tresto

4 years ago

Ex­clu­sive: A year in­to his role, Ipsen's CBO is on a $3B mis­sion to get the com­pa­ny 'back on the right track'

4 years ago
People

Har­poon CEO re­signs in wake of dwin­dling mar­ket cap and slid­ing stock price

4 years ago
People

Bausch Health’s Sal­ix pi­lots study to shine light on chron­ic liv­er dis­ease and push back on stereo­types

4 years ago
Marketing

Sim­mer­ing feud be­tween blue­bird and a ri­val con­tin­ues with al­le­ga­tions of patent fraud

4 years ago
Cell/Gene Tx

A com­bo of As­traZeneca's Imfinzi and chemo wins where oth­ers have failed in piv­otal bil­iary tract test

4 years ago

Re­cent court de­ci­sion push­es FDA to re­ject and re­clas­si­fy drug-de­vice com­bo, crush­ing shares

4 years ago
FDA+

Sanofi, Re­gen­eron gear up for new Dupix­ent fil­ing af­ter clear­ing sec­ond PhI­II for eosinophilic esophagi­tis

4 years ago
R&D

On­copep­tides stock craters as it pulls can­cer drug Pepax­to from the mar­ket

4 years ago
FDA+

Fol­low­ing Au­gust melt­down, Zymer­gen hints at sal­vage plans — cut­ting jobs and rene­go­ti­at­ing loans

4 years ago

Sanofi, Re­gen­eron etch out an­oth­er PhI­II vic­to­ry for Dupix­ent, eas­ing se­vere itch and clear­ing le­sions

4 years ago
R&D

Eli Lil­ly or­dered to pay roy­al­ties on block­buster di­a­betes drugs, though ex­act dam­ages are un­clear

4 years ago

Te­va ap­peals to court to keep 'in­cred­i­bly dam­ag­ing' Hol­ly­wood par­o­dy videos un­der wraps in New York opi­oid case

4 years ago
Marketing

Bris­tol My­ers pledges to sell its Ac­celeron shares as ac­tivist in­vestors cir­cle Mer­ck­'s $11.5B buy­out — re­port

4 years ago
Deals

'No ex­cuse': ICER de­ter­mines As­traZeneca's new mon­ey­mak­er Soliris is vast­ly over­priced

4 years ago
Deals
First page Previous page 229230231232233234235 Next page Last page
A service from the Financial Times